INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
INTENSITY THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.29−0.06 (-1.79%)
Close on Oct 19, 2026
- Market cap
- $8.90M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.23 (−49.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $8.90M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.97
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.16M
- EPS, diluted
- -$8.56
- Book value per share
- $3.40
- Diluted shares
- 3M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$11.48M
Net income
-$11.16M
EPS, diluted
–
Reported periodTrailing twelve months